Relay Therapeutics Stock Technical Analysis
| RLAY Stock | USD 8.62 0.00 0.00% |
As of the 9th of February, Relay Therapeutics holds the Semi Deviation of 3.35, coefficient of variation of 955.67, and Risk Adjusted Performance of 0.0926. Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Relay Therapeutics, as well as the relationship between them.
Relay Therapeutics Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Relay, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to RelayRelay Therapeutics' Momentum analyses are specifically helpful, as they help investors time the market using mark points where the market can reverse. The reversal spots are usually identified through divergence between price movement and momentum.Relay Therapeutics Analyst Consensus
| Target Price | Consensus | # of Analysts | |
| 14.55 | Strong Buy | 13 | Odds |
Most Relay analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Relay stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Relay Therapeutics, talking to its executives and customers, or listening to Relay conference calls.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Relay Therapeutics. Anticipated expansion of Relay directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Relay Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (1.72) | Revenue Per Share | Quarterly Revenue Growth (0.23) | Return On Assets | Return On Equity |
The market value of Relay Therapeutics is measured differently than its book value, which is the value of Relay that is recorded on the company's balance sheet. Investors also form their own opinion of Relay Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Relay Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Relay Therapeutics' market value can be influenced by many factors that don't directly affect Relay Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Relay Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Relay Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Relay Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Relay Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Relay Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Relay Therapeutics.
| 11/11/2025 |
| 02/09/2026 |
If you would invest 0.00 in Relay Therapeutics on November 11, 2025 and sell it all today you would earn a total of 0.00 from holding Relay Therapeutics or generate 0.0% return on investment in Relay Therapeutics over 90 days. Relay Therapeutics is related to or competes with Syndax Pharmaceuticals, Oric Pharmaceuticals, Amylyx Pharmaceuticals, Inhibrx Biosciences, Upstream Bio, Nektar Therapeutics, and Immatics. Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company More
Relay Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Relay Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Relay Therapeutics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.64 | |||
| Information Ratio | 0.0851 | |||
| Maximum Drawdown | 30.68 | |||
| Value At Risk | (5.45) | |||
| Potential Upside | 6.4 |
Relay Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Relay Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Relay Therapeutics' standard deviation. In reality, there are many statistical measures that can use Relay Therapeutics historical prices to predict the future Relay Therapeutics' volatility.| Risk Adjusted Performance | 0.0926 | |||
| Jensen Alpha | 0.407 | |||
| Total Risk Alpha | 0.0165 | |||
| Sortino Ratio | 0.1076 | |||
| Treynor Ratio | 0.5859 |
Relay Therapeutics February 9, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0926 | |||
| Market Risk Adjusted Performance | 0.5959 | |||
| Mean Deviation | 3.22 | |||
| Semi Deviation | 3.35 | |||
| Downside Deviation | 3.64 | |||
| Coefficient Of Variation | 955.67 | |||
| Standard Deviation | 4.6 | |||
| Variance | 21.13 | |||
| Information Ratio | 0.0851 | |||
| Jensen Alpha | 0.407 | |||
| Total Risk Alpha | 0.0165 | |||
| Sortino Ratio | 0.1076 | |||
| Treynor Ratio | 0.5859 | |||
| Maximum Drawdown | 30.68 | |||
| Value At Risk | (5.45) | |||
| Potential Upside | 6.4 | |||
| Downside Variance | 13.23 | |||
| Semi Variance | 11.22 | |||
| Expected Short fall | (3.78) | |||
| Skewness | 1.38 | |||
| Kurtosis | 5.16 |
Relay Therapeutics Backtested Returns
Relay Therapeutics appears to be somewhat reliable, given 3 months investment horizon. Relay Therapeutics maintains Sharpe Ratio (i.e., Efficiency) of 0.13, which implies the firm had a 0.13 % return per unit of risk over the last 3 months. By analyzing Relay Therapeutics' technical indicators, you can evaluate if the expected return of 0.61% is justified by implied risk. Please evaluate Relay Therapeutics' Risk Adjusted Performance of 0.0926, semi deviation of 3.35, and Coefficient Of Variation of 955.67 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Relay Therapeutics holds a performance score of 10. The company holds a Beta of 0.8, which implies possible diversification benefits within a given portfolio. As returns on the market increase, Relay Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Relay Therapeutics is expected to be smaller as well. Please check Relay Therapeutics' value at risk, as well as the relationship between the kurtosis and price action indicator , to make a quick decision on whether Relay Therapeutics' historical price patterns will revert.
Auto-correlation | -0.07 |
Very weak reverse predictability
Relay Therapeutics has very weak reverse predictability. Overlapping area represents the amount of predictability between Relay Therapeutics time series from 11th of November 2025 to 26th of December 2025 and 26th of December 2025 to 9th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Relay Therapeutics price movement. The serial correlation of -0.07 indicates that barely 7.0% of current Relay Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.07 | |
| Spearman Rank Test | -0.07 | |
| Residual Average | 0.0 | |
| Price Variance | 0.18 |
Relay Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Relay Therapeutics Technical Analysis
The output start index for this execution was one with a total number of output elements of sixty. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Relay Therapeutics volatility. High ATR values indicate high volatility, and low values indicate low volatility.
About Relay Therapeutics Technical Analysis
The technical analysis module can be used to analyzes prices, returns, volume, basic money flow, and other market information and help investors to determine the real value of Relay Therapeutics on a daily or weekly bases. We use both bottom-up as well as top-down valuation methodologies to arrive at the intrinsic value of Relay Therapeutics based on its technical analysis. In general, a bottom-up approach, as applied to this company, focuses on Relay Therapeutics price pattern first instead of the macroeconomic environment surrounding Relay Therapeutics. By analyzing Relay Therapeutics's financials, daily price indicators, and related drivers such as dividends, momentum ratios, and various types of growth rates, we attempt to find the most accurate representation of Relay Therapeutics's intrinsic value. As compared to a bottom-up approach, our top-down model examines the macroeconomic factors that affect the industry/economy before zooming in to Relay Therapeutics specific price patterns or momentum indicators. Please read more on our technical analysis page.
| 2023 | 2024 | 2025 | 2026 (projected) | Net Debt To EBITDA | 0.24 | 0.2 | 0.23 | 0.22 | Intangibles To Total Assets | 0.002725 | 0.00264 | 0.002376 | 0.001947 |
Relay Therapeutics February 9, 2026 Technical Indicators
Most technical analysis of Relay help investors determine whether a current trend will continue and, if not, when it will shift. We provide a combination of tools to recognize potential entry and exit points for Relay from various momentum indicators to cycle indicators. When you analyze Relay charts, please remember that the event formation may indicate an entry point for a short seller, and look at different other indicators across different periods to confirm that a breakdown or reversion is likely to occur.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0926 | |||
| Market Risk Adjusted Performance | 0.5959 | |||
| Mean Deviation | 3.22 | |||
| Semi Deviation | 3.35 | |||
| Downside Deviation | 3.64 | |||
| Coefficient Of Variation | 955.67 | |||
| Standard Deviation | 4.6 | |||
| Variance | 21.13 | |||
| Information Ratio | 0.0851 | |||
| Jensen Alpha | 0.407 | |||
| Total Risk Alpha | 0.0165 | |||
| Sortino Ratio | 0.1076 | |||
| Treynor Ratio | 0.5859 | |||
| Maximum Drawdown | 30.68 | |||
| Value At Risk | (5.45) | |||
| Potential Upside | 6.4 | |||
| Downside Variance | 13.23 | |||
| Semi Variance | 11.22 | |||
| Expected Short fall | (3.78) | |||
| Skewness | 1.38 | |||
| Kurtosis | 5.16 |
Relay Therapeutics February 9, 2026 Daily Trend Indicators
Traders often use several different daily volumes and price technical indicators to supplement a more traditional technical analysis when analyzing securities such as Relay stock. With literally thousands of different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 0.08 | ||
| Daily Balance Of Power | 0.00 | ||
| Rate Of Daily Change | 1.00 | ||
| Day Median Price | 8.67 | ||
| Day Typical Price | 8.65 | ||
| Price Action Indicator | (0.05) | ||
| Market Facilitation Index | 0.68 |
Additional Tools for Relay Stock Analysis
When running Relay Therapeutics' price analysis, check to measure Relay Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Relay Therapeutics is operating at the current time. Most of Relay Therapeutics' value examination focuses on studying past and present price action to predict the probability of Relay Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Relay Therapeutics' price. Additionally, you may evaluate how the addition of Relay Therapeutics to your portfolios can decrease your overall portfolio volatility.